PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism
Open Access
- 25 May 2022
- journal article
- research article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (1) , 157-173
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Tianjin Municipality (21JCZDJC00060)
- National Natural Science Foundation of China (81902826, 81672781, 81973356, 91957120)
- State Key Laboratory of Drug Research, Chinese Academy of Sciences (SIMM2105KF-08)
- Fundamental Research Funds for the Central Universities (3206054, 92122017, 91923101, 63213082)
- National Key Research and Development Program of China (2018YFC2002000)
This publication has 25 references indexed in Scilit:
- CARM1 Methylates GAPDH to Regulate Glucose Metabolism and Is Suppressed in Liver CancerCell Reports, 2018
- Development of Potent Type I Protein Arginine Methyltransferase (PRMT) Inhibitors of Leukemia Cell ProliferationJournal of Medicinal Chemistry, 2017
- Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung CancerFrontiers in Pharmacology, 2017
- Arginine Methylation: The Coming of AgeMolecular Cell, 2017
- Arginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic CancerMolecular Cell, 2016
- Effect of phosphorylation and methylation on the function of the p16INK4a protein in non-small cell lung cancer A549 cellsOncology Letters, 2015
- Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathwayNature Communications, 2014
- Post-translational modifications and the Warburg effectOncogene, 2013
- Protein arginine methyltransferases and cancerNature Reviews Cancer, 2012
- Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancersInternational Journal of Cancer, 2010